Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021
MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer…